Ontology highlight
ABSTRACT:
SUBMITTER: Ortiz M
PROVIDER: S-EPMC9255249 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
Ortiz Mylena M Wabel Emma E Mitchell Kerry K Horibata Sachi S
Cancer drug resistance (Alhambra, Calif.) 20220403 2
Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (olaparib and niraparib) and one vascular endothelial growth factor inhibitor (bevacizumab) as maintenance therapies for ovarian cancer. In this review, we summarize the resistance mechanisms for conve ...[more]